Results

Total Results: 1,541 records

Showing results for "months".

1. Cer-265-Radiation-Bone-Disease-Addendum-App (xls file)
   effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-265-radiation-bone-disease-addendum-app.xlsx
   May 29, 2025 - : 139 (39.4%); 6 months: 246 (69.7%), 12 months: 356 (72.5%); 24 months: 306 (86.7%) A: SBRT, 16 Gy or … 6 months 12 months 24 months A vs. … : -2.98 (3.34) vs. -3.83 (2.97) 6 months: -3.07 (3.50) vs. -3.85 (2.56) 12 months: -3.34 (3.25) vs. - … 4.7 6 months: 4.8 vs. 3.9 12 months: 4.7 vs. 4.5 FACT-G, mean Baseline: 69 vs. 70 3 months: 75 vs … . 78 6 months: 78 vs. 77 12 months: 71 vs. 73 A vs.

2. Data-Points-7-Tables1 (xls file)
   effectivehealthcare.ahrq.gov/sites/default/files/data-points-7-tables1.xls
   May 29, 2025 - 3.80% - - 92.41% 9.81% - 37.34% - - 9.18% 6.01% 5.06% 9.49% Kinase Inhibitors GEFITINIB 6 months - … - 3.53% 94.87% 13.14% - 41.03% - - 13.78% 9.29% 8.65% 12.82% Kinase Inhibitors GEFITINIB 12 months … Kinase Inhibitors PAZOPANIB 3 months . 90.32% . . 96.77% . . . . … Kinase Inhibitors PAZOPANIB 6 months . 96.67% . . 100.00% . . 36.67% . … Kinase Inhibitors PAZOPANIB 12 months . 100.00% . . 100.00% . . 42.31% .

3. Data-Points-7-Tables (xls file)
   effectivehealthcare.ahrq.gov/sites/default/files/data-points-7-tables.xls
   May 29, 2025 - 3.80% - - 92.41% 9.81% - 37.34% - - 9.18% 6.01% 5.06% 9.49% Kinase Inhibitors GEFITINIB 6 months - … - 3.53% 94.87% 13.14% - 41.03% - - 13.78% 9.29% 8.65% 12.82% Kinase Inhibitors GEFITINIB 12 months … Kinase Inhibitors PAZOPANIB 3 months . 90.32% . . 96.77% . . . . … Kinase Inhibitors PAZOPANIB 6 months . 96.67% . . 100.00% . . 36.67% . … Kinase Inhibitors PAZOPANIB 12 months . 100.00% . . 100.00% . . 42.31% .

4. Data-Points-7-Tables1 (pdf file)
   effectivehealthcare.ahrq.gov/sites/default/files/data-points-7-tables1.pdf
   May 29, 2025 - 7.3 * 9.5 13.1 41.9 37.7 56.0 7.2 * 6.2 4.9 10.6 7.2 Biologic response modifiers Aldesleukin 3 months … 0.9 0.2 2.0 1.5 6.1 98.0 3.9 1.6 0.0 17.0 25.9 26.9 46.8 Biologic response modifiers BCG 6 months … 1.1 * 3.5 1.3 8.1 1.7 5.4 95.5 * 7.2 1.6 15.8 2.6 Kinase inhibitors Dasatinib 6 months * * 4.2 1.8 … 0.3 1.9 21.5 82.9 12.8 4.1 63.9 3.4 0.2 11.4 8.8 13.5 17.7 Kinase inhibitors Erlotinib 6 months 0.3 … 2.3 23.1 83.4 16.4 5.0 69.4 4.3 0.2 17.5 11.4 19.4 23.6 Kinase inhibitors Erlotinib 12 months 0.2

5. Data-Points-7-Tables (pdf file)
   effectivehealthcare.ahrq.gov/sites/default/files/data-points-7-tables.pdf
   May 29, 2025 - 7.3 * 9.5 13.1 41.9 37.7 56.0 7.2 * 6.2 4.9 10.6 7.2 Biologic response modifiers Aldesleukin 3 months … 0.9 0.2 2.0 1.5 6.1 98.0 3.9 1.6 0.0 17.0 25.9 26.9 46.8 Biologic response modifiers BCG 6 months … 1.1 * 3.5 1.3 8.1 1.7 5.4 95.5 * 7.2 1.6 15.8 2.6 Kinase inhibitors Dasatinib 6 months * * 4.2 1.8 … 0.3 1.9 21.5 82.9 12.8 4.1 63.9 3.4 0.2 11.4 8.8 13.5 17.7 Kinase inhibitors Erlotinib 6 months 0.3 … 2.3 23.1 83.4 16.4 5.0 69.4 4.3 0.2 17.5 11.4 19.4 23.6 Kinase inhibitors Erlotinib 12 months 0.2

6. Appendix-E-Table-E5 0 (xls file)
   effectivehealthcare.ahrq.gov/sites/default/files/related_files/Appendix-E-Table-E5_0.xlsx
   May 29, 2025 - NR + 1.75 mg/d 3 months: 3.15 mg/d vs. 2,372 mg/d vs. … NR + 2.85 mg/d 6 months: 3.05 mg/d + 2,295.5 mg/d vs. … NR 6 months: 38% (21/49) vs. 48% (31/52) vs. … . 23% (12/52) vs. 9% (5/55) Sedation 3 months: 31% (15/49) vs. 54% (28/52) vs. 33% (18/55) 6 months: … NA 84 (21 months) Long NR None NR NR NR NR NR A vs.

7. Cannabis-App-F5-Table-Surveillance-Report-2 0 0 (xls file)
   effectivehealthcare.ahrq.gov/sites/default/files/related_files/cannabis-app-f5-table-surveillance-report-2_0_0.xlsx
   May 29, 2025 - NR + 1.75 mg/d 3 months: 3.15 mg/d vs. 2,372 mg/d vs. … NR + 2.85 mg/d 6 months: 3.05 mg/d + 2,295.5 mg/d vs. … NR 6 months: 38% (21/49) vs. 48% (31/52) vs. … . 23% (12/52) vs. 9% (5/55) Sedation 3 months: 31% (15/49) vs. 54% (28/52) vs. 33% (18/55) 6 months: … NA 84 (21 months) Long NR None NR NR NR NR NR A vs.

8. Cannabis-2023-Surv-Rep-4-Table-E-5 (xls file)
   effectivehealthcare.ahrq.gov/sites/default/files/related_files/cannabis-2023-surv-rep-4-table-E-5.xlsx
   January 01, 2023 - NR + 1.75 mg/d 3 months: 3.15 mg/d vs. 2,372 mg/d vs. … NR + 2.85 mg/d 6 months: 3.05 mg/d + 2,295.5 mg/d vs. … NR + 3.02 mg/d 26 (6 months) Short and intermediate A vs. B vs. … NA CBD: 202.18 (SD 345.23) 12 weeks (3 months) Short A vs. … NA 84 (21 months) Long NR None NR NR NR NR NR A vs.

9. Cannabis-2022-Surv-Rep-4-Table-F5 (xls file)
   effectivehealthcare.ahrq.gov/sites/default/files/related_files/cannabis-2022-surv-rep-4-table-F5.xlsx
   January 01, 2022 - NR + 1.75 mg/d 3 months: 3.15 mg/d vs. 2,372 mg/d vs. … NR + 2.85 mg/d 6 months: 3.05 mg/d + 2,295.5 mg/d vs. … NR + 3.02 mg/d 26 (6 months) Short and intermediate A vs. B vs. … NA CBD: 202.18 (SD 345.23) 12 weeks (3 months) Short A vs. … NA 84 (21 months) Long NR None NR NR NR NR NR A vs.

10. Cer-250-Cannabis-2025-Surv-Rep-Update-Table-E5 (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-250-cannabis-2025-surv-rep-update-table-e5.xlsx
    January 01, 2025 - NR + 1.75 mg/d 3 months: 3.15 mg/d vs. 2,372 mg/d vs. … NR + 2.85 mg/d 6 months: 3.05 mg/d + 2,295.5 mg/d vs. … NR + 3.02 mg/d 26 (6 months) Short and intermediate A vs. B vs. … NA CBD: 202.18 (SD 345.23) 12 weeks (3 months) Short A vs. … NA 84 (21 months) Long NR None NR NR NR NR NR A vs.

11. Executive Summary_Comparative Effectiveness Review No. 261_Postpartum Care up to 1 Year After Pregnancy: A Systematic Review and Meta-Analysis (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-261-postpartum-care-executive-summary.pdf
    June 01, 2023 - postpartum), anxiety symptoms (up to 2 months), hospital readmission (up to 3 months), or other unplanned … but not at 1 month or 3 months. … and 6 months and of exclusive breastfeeding at 3 months (all moderate SoE) … by 3 months or other unplanned care utilization up to 2 months). … but not at 1 month or 3 months.

12. Evidence Summary_Comparative Effectiveness Review No. 247_Interventional Treatments for Acute and Chronic Pain: Systematic Review (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-247-interventional-treatments-acute-chronic-pain-evidence-summary_0.pdf
    September 01, 2021 - Outcomes were analyzed at 1 to 2 weeks, 2 to 4 weeks, 1 to 6 months, 6 to 12 months, and 12 months and … (10 trials, N=1094), 6 to 12 months (8 trials, N=993), and 12 months and longer (9 trials, N=965), … (7 trials, N=637), 6 to 12 months (6 trials, N=690), and ≥12 months (6 trials, N=612). … 2 to 4 weeks and 6 to 12 months) … at 6 weeks and 3 months; insufficient for 6, 12, and 24 months).

13. Cer-250-Cannabis-2024-Surv-Rep-Update-Table-E5 (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-250-cannabis-2024-surv-rep-update-table-e5.xlsx
    January 01, 2024 - NR + 1.75 mg/d 3 months: 3.15 mg/d vs. 2,372 mg/d vs. … NR + 2.85 mg/d 6 months: 3.05 mg/d + 2,295.5 mg/d vs. … NR + 3.02 mg/d 26 (6 months) Short and intermediate A vs. B vs. … NA CBD: 202.18 (SD 345.23) 12 weeks (3 months) Short A vs. … NA 84 (21 months) Long NR None NR NR NR NR NR A vs.

14. Cer-251-Integrated-Pain-Management-App-F (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/cer-251-integrated-pain-management-app-F.xlsx
    January 01, 2020 - : Yes 24 months: Overall No, Differential Yes Yes Yes Fair Table G-1. … : Yes 18 months: Overall Yes; Differential No Yes Yes Fair Johansson, 1998 Unclear Unclear Unclear … : Yes 24 months: Overall No, Differential Yes Yes Yes Fair Kool 2005/2007 Yes Yes Yes Yes No No Yes … : Yes 12 months: Overall, No; Differential, Yes Yes Yes Fair Tavafian 2011, 2014, 2017a, 2017b Yes … Yes Yes Yes No No Yes 3, 6, 12, 24 months: Yes; 30 months: Overall No, Differential Yes No Yes Fair

15. Antibody Response Following SARS-CoV-2 Infection and Implications for Immunity: Final Update of a Rapid, Living Review (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/version-3-immunity-after-COVID-19.pdf
    December 31, 2022 - ^ 27/41 (66%) — 3 months^ 21/31 (68%) — 6 months^ 16/18 (89%) — 1 month^ 17/18 (94%) — 3 months^ … 6 months^ 18/18 (100%) — 1 month^ NR/NR (89%) — 3 months^ NR/NR (65%) — 6 months^ Marra, 2020 … IgG anti-S NR/NR (95%) — 3 months NR/NR (90%) — 6 months 30/34 (88%) — 12 months NR/NR (97%) — 3 … months NR/NR (94%) — 6 months 50/50 (100%) — 12 months 20 Population Author, … anti-S 21/22 (96%) — 1 month 37/46 (80%) — 3 months 38/45 (84%) — 6 months 23/28 (82%) — 9 months

16. Cer-250-Cannabis-Table-E5-2022-Update 0 (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-250-cannabis-table-e5-2022-update_0.xlsx
    January 01, 2022 - NR + 1.75 mg/d 3 months: 3.15 mg/d vs. 2,372 mg/d vs. … NR + 2.85 mg/d 6 months: 3.05 mg/d + 2,295.5 mg/d vs. … NR + 3.02 mg/d 26 (6 months) Short and intermediate A vs. B vs. … NA CBD: 202.18 (SD 345.23) 12 weeks (3 months) Short A vs. … NA 84 (21 months) Long NR None NR NR NR NR NR A vs.

17. Version-3-Immunity-After-Covid-19-Appendix-Table-B-1 (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/version-3-immunity-after-COVID-19-appendix-table-B-1.xlsx
    January 24, 2022 - Sample collection post-infection: T0: 2 months T1: 3 months T2: 5 months T3: 7 months T4: 8 months T5 … : 10 months T6: 12 months T7: 13 months T8: 14 months NR Mild: 19 (59.3) Moderately severe: 13 (40.7 … : 46 (40-53) 6 months: 46 (40-53) 13 months: 47 (41-54) NR 2 months: 5 (10) 6 months: 11 (11) 13 months … Post-outbreak 2 months 6 months 13 months Asymptomatic (out of PCR+ participants) 2 months: 12/45 (26.7 … 3-6 months 6-9 months >=9 months NR NR NR.

18. App-D-Surv-Report-3-Noninvasive-Nonpharma 0 (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-d-surv-report-3-noninvasive-nonpharma_0.xlsx
    January 01, 2022 - : 112 - 6 months: 116 - 12 months: 124 Attrition: - 3 months: 26% (39/151) - 6 months: 23% (35/151) … - 12 months: 18% (27/151) A. … and monthly thereafter (total of 24 sessions over 18 months). … Higher scores indicate higher symptom severity. 10 months A vs. … B 3 months post-intervention / 9 months from baseline WOMAC pain: 5.3 (3.9) vs. 6.5 (3.7), p=NR; MD –

19. App-D-Surv-Report-1-Noninvasive-Nonpharma 0 (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-d-surv-report-1-noninvasive-nonpharma_0.xlsx
    January 01, 2021 - NR, adj MD −0.2 (95% CI −0.7 to 0.2), p=0.33 10.5 months FIQ: NR vs. … C 6 months Opioid Days: 1.61 (0.91) vs. 2.93 (0.93), p=0.31 B vs. … and monthly thereafter (total of 24 sessions over 18 months). … Higher scores indicate higher symptom severity. 10 months A vs. … B 3 months post-intervention / 9 months from baseline WOMAC pain: 5.3 (3.9) vs. 6.5 (3.7), p=NR; MD –

20. App-D-Surv-Report-2-Noninvasive-Nonpharma (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-d-surv-report-2-noninvasive-nonpharma.xlsx
    January 01, 2021 - NR, adj MD −0.2 (95% CI −0.7 to 0.2), p=0.33 10.5 months FIQ: NR vs. … C 6 months Opioid Days: 1.61 (0.91) vs. 2.93 (0.93), p=0.31 B vs. … and monthly thereafter (total of 24 sessions over 18 months). … Higher scores indicate higher symptom severity. 10 months A vs. … B 3 months post-intervention / 9 months from baseline WOMAC pain: 5.3 (3.9) vs. 6.5 (3.7), p=NR; MD –